Nereid Therapeutics will advance research by Clifford Brangwynne of Princeton University following its launch with a $50m series A round from Apple Tree Partners.

Nereid Therapeutics, a US-based developer of treatments for cancer and neurodegenerative diseases based on research at Princeton University, was launched this week by venture firm Apple Tree Partners with $50m in series A capital. Nereid will develop therapies targeting biomolecular condensates, a specialised subunit of the cell, using research by scientific founder Clifford Brangwynne, a…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.